Abstract

BackgroundAdjuvant chemotherapy improves outcome of patients with early breast cancer. However, chemotherapy may be associated with long term toxicities. In this retrospective cohort study, the objectives were to determine body weight, body mass index (BMI), blood pressure and fasting lipids levels of young premenopausal Chinese breast cancer patients after adjuvant chemotherapy. Potential factors associated with these parameters were identified.MethodsEligibility criteria include premenopausal Chinese patients who were diagnosed to have stage I-III breast cancer within 3–10 years, age < 45 and having received adjuvant chemotherapy at the time of breast cancer diagnosis. Information at initial breast cancer diagnosis were retrieved from patients’ medical records and include age at diagnosis, tumor characteristics, anti-cancer treatments, blood pressure and body weight and height. At study entry, all patients had additional background demographics collected, as well as blood pressure, body weight and fasting serum lipid profiles measured. Incidence of chemotherapy-related amenorrhoea (CRA) and menopause were determined. Factors associated with weight gain, hypertension and dyslipidaemias were analyzed.ResultsTwo hundred and eighty patients were studied. The median age at breast cancer diagnosis was 41 years (range: 24–45). The median time from breast cancer diagnosis to study entry was 5.0 years. The median age at study entry was 46.5 years (range: 28–54). 91.1% developed CRA; 48.9% had become menopausal and 10% were peri-menopausal. Between initial breast cancer diagnosis and the time of study entry, the median weight gain was 1.8 kg; 63.2% gained weight by >2%; 52.1% were overweight/obese; 30.7% had hypertension. Abnormal total-cholesterol and LDL-cholesterol occurred in 34.3% and 56.1% respectively. On multivariate analyses, older age was associated with reduced risk while occurrence of CRA and having received taxane-containing regimens were associated with increased risk of weight gain. Oestrogen-receptor positivity was associated with reduced risk while overweight/obese statuses were associated with increased risk of hypertension. Use of tamoxifen was associated with reduced risk of abnormal LDL-cholesterol. Weight gain, overweight/obese, older age, progression to post/peri-menopausal status at study entry, having received corticosteroid premedication before adjuvant chemotherapy and having received taxane-containing adjuvant chemotherapy were associated with increased risk of dyslipidaemias.ConclusionAmong young premenopausal Chinese breast cancer patients who had received adjuvant chemotherapy, the current study has revealed that although there was only a median weight gain of 1.8 kg, there was a nearly 60% increase in abnormal BMI. Further, a significant proportion of patients were detected to have hypertension and dyslipidaemias. Interventional studies with lifestyle modifications are warranted.

Highlights

  • Adjuvant chemotherapy improves outcome of patients with early breast cancer

  • Apart from weight gain and obesity which is associated with detrimental effect on health profiles, anti-cancer drugs, the anthracyclines and anti-human epidermal growth factor receptor 2 (HER2) agents that are commonly used in breast cancer, could cause cardiotoxicity and may further increase the cardiovascular risk of the patients concerned [16]

  • The present study assessed only young premenopausal Chinese patients with a protracted interval of 5 years after adjuvant chemotherapy, 63% had gained weight by >2% and the average gain was 1.8 kg; this figure appeared to be small, one cannot overlook the proportion of patients who were detected to have abnormal body mass index (BMI), as this had increased by nearly 60%, from 33% at breast cancer diagnosis to 52% at study entry

Read more

Summary

Introduction

Chemotherapy may be associated with long term toxicities In this retrospective cohort study, the objectives were to determine body weight, body mass index (BMI), blood pressure and fasting lipids levels of young premenopausal Chinese breast cancer patients after adjuvant chemotherapy. Some of the chemotherapy-related long term toxicities include chemotherapy-related amenorrhoea (CRA) and early menopause, as well as anthropometric and metabolic changes that could lead to increased cardiovascular risk [5, 6]. Apart from weight gain and obesity which is associated with detrimental effect on health profiles, anti-cancer drugs, the anthracyclines and anti-human epidermal growth factor receptor 2 (HER2) agents that are commonly used in breast cancer, could cause cardiotoxicity and may further increase the cardiovascular risk of the patients concerned [16]. While change in menopausal status and increased body weight have been well-linked to the use of adjuvant chemotherapy, the association of these changes with cardiovascular comorbidities, aspects on blood pressure and lipids profiles, are less well-known

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call